Die EV-Plattform, gebaut für die reale Welt.
Most exosome products cannot tell you what is in the vial. We can. BioThera isolates plant-derived extracellular vesicles at manufacturing scale, counts them by Nanoparticle Tracking Analysis, and characterizes every batch against MISEV2023 — the consensus standard our founder helped write. One platform, one Certificate of Analysis, many applications.
Extrazeluläres Vesikel (EV/Exosom)
Echtzeit-Strukturmodell der bioaktiven Moleküle in diesem nanoskaligen Trägersystem
Was macht BioThera Solutions?
BioThera Solutions operates across three integrated layers: plant-derived EV isolation and MISEV2023-compliant biomanufacturing, rigorous particle characterization, and formulation into finished applications. The same workflow supplies every application built on the platform, and every batch leaves with the Certificate of Analysis behind it.
EV Biomanufacturing
Scalable. Standardized. Reproducible.
Proprietary isolation and scale-up engineered for consistency — batch-level characterization, cold-chain integrity, and standardized quality control across plant-derived EV modalities.
Characterization & Standards
MISEV2023, by a named contributor.
Every batch is counted by Nanoparticle Tracking Analysis, screened for contaminants, and characterized against the MISEV2023 marker framework. The number on the Certificate of Analysis is a measured number, not an estimate.
Applications
One platform, several end markets.
The same workflow supplies skincare and dermocosmetics today, and is being evaluated against clinical dermatology, wound and barrier repair, regenerative medicine, and drug delivery. One isolation and characterization process behind all of them.
One process. Several end markets.
BioThera isolates plant-derived extracellular vesicles, characterizes them against MISEV2023, and documents every batch. Formulation is downstream of that. The areas below are where the platform applies, each with an honest note on how far it has actually gone.
- Skincare & dermocosmetics: supplied exclusively to Vesera™, a dermocosmetic brand
- Clinical dermatology: in evaluation
- Wound & barrier repair: research direction
- Regenerative medicine: research direction
- Drug delivery: research direction
Building on plant-derived exosomes? Start a conversation.
We work with research, clinical and industry partners. Whether you are exploring co-development, licensing or a research collaboration, reach out.